Amplia Therapeutics (ASX:ATX)’s share price traded down 8% during mid-day trading on Friday . The company traded as low as A$0.08 ($0.06) and last traded at A$0.08 ($0.06), 50,000 shares changed hands during mid-day trading. The stock had previously closed at A$0.09 ($0.06).

The stock has a market cap of $3.57 million and a PE ratio of -1.70.

Amplia Therapeutics Company Profile (ASX:ATX)

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits FAK. The company also manufactures and sells drugs.

Further Reading: Penny Stocks

Receive News & Ratings for Amplia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.